YoungSolvers Webinar: Stumbling Blocks in Drug Design – Applied Medicinal Chemistry

webinar

Tue, 17 Aug 2021, 16:00 CEST (Berlin)

Alexander Neumann

YoungSolvers Webinar: Stumbling Blocks in Drug Design – Applied Medicinal Chemistry

What happens in silico does not have to stay in silico. Although some compounds may appear as very promising drug candidates due to high docking scores or phenomenal affinity predictions, they need subsequent validation to avoid in vivo and in vitrodisenchantment. In this webinar interdisciplinary aspects of medicinal chemistry in computer-aided drug design will be discussed and elucidated. We will adress which molecular scaffolds and functional groups can cause problems during lead-optimization, how to read and digest predicted physicochemical properties, where to search for solutions, as well as many other related topics. A must for every medicinal and computational chemistry enthusiast.

Level: Advanced

Current news

Tool of the Month - infiniSee 7.1 'Arke'
May 27, 2026 09:44 CEST
Navigate Chemical Space with infiniSee 7.1 ‘Arke’ The ultimate platform for exploring ultra-large Chemical Spaces is taking a huge leap forward. Combining our Tool of the Month series with an exciting software release, we are happy to present infiniSee 7.1 ‘Arke’. Allowing you to search deeper and evaluate compounds more...
Read on
category
Software
infiniSee 7.1 'Arke' Is Now Available
May 26, 2026 16:49 CEST
We are delighted to introduce infiniSee 7.1 ‘Arke’, another helpful step forward in making the exploration of vast Chemical Spaces faster, clearer, and more intuitive. With this update, we focused on two central goals: helping users move through ultra-large Chemical Spaces more efficiently and making compound assessment more visual and...
Read on
VAST™ Space by XtalPi - Access now with our tools
May 21, 2026 10:42 CEST
The VAST™ Space brings an actionable, navigable universe of 4.66 billion accessible, drug-like products directly into your workflow. Created by XtalPi, this collection was built from 40+ validated reaction protocols and 58,000 in-stock building blocks. By pairing automated synthesis with proprietary feasibility models, it delivers a highly reliable and innovative...
Read on